Utility of 68 Ga-FAPI-04 PET/CT in Adenoid Cystic Carcinoma Compared With 18 F-FDG PET/CT : Two Case Reports

Clin Nucl Med. 2023 Jul 1;48(7):e350-e352. doi: 10.1097/RLU.0000000000004687. Epub 2023 May 11.

Abstract

68 Ga-fibroblast activation protein inhibitor (FAPI) PET/CT is an emerging imaging modality with high sensitivity and high tumor-to-background ratio in various cancers including in the head and neck regions. The authors present 2 cases of adenoid cystic carcinoma who underwent 68 Ga-FAPI-04 and 18 F-FDG PET/CT. Locoregional recurrence has been detected more precisely in the first case with 68 Ga-FAPI-04. In the second case, 68 Ga-FAPI-04 outperformed 18 F-FDG in the number of lesions and demonstrated intense FAP uptake on widespread metastases, which could provide a treatment option as a theranostic concept. These cases highlight that 68 Ga-FAPI-04 PET/CT may be useful for detecting local recurrence and metastases and help select patients for radionuclide treatments targeting cancer-associated fibroblasts.

Publication types

  • Case Reports

MeSH terms

  • Carcinoma, Adenoid Cystic* / diagnostic imaging
  • Fluorodeoxyglucose F18
  • Gallium Radioisotopes
  • Humans
  • Neoplasm Recurrence, Local
  • Positron Emission Tomography Computed Tomography*

Substances

  • Fluorodeoxyglucose F18
  • 68Ga-FAPI
  • Gallium-68
  • Gallium Radioisotopes